[Translation] A randomized, open-label, single-dose, two-formulation, two-sequence, two-period, self-crossover controlled design was used to evaluate the bioequivalence of the test formulation loxoprofen sodium patch and the reference formulation loxoprofen sodium patch in Chinese healthy trial participants under fasting conditions.
主要目的:观察健康试验参与者空腹状态下单剂量使用受试制剂洛索洛芬钠贴剂(规格:100mg/贴(10cm×14cm),生产厂家:浙江赛默制药有限公司)后血药浓度的经时过程,估算相应的药代动力学参数;并以洛索洛芬钠贴剂(规格:100mg/贴(10cm×14cm),持证商:LEAD CHEMICAL CO., LTD.)为参比制剂,进行人体生物等效性正式试验,为该药注册申报和临床应用提供参考依据。
次要目的:观察试验参与者空腹状态下使用受试制剂和参比制剂的安全性、黏附性和皮肤刺激性。
[Translation] Primary Objective: To observe the time-dependent progression of blood drug concentration after a single dose of the test formulation, loxoprofen sodium patch (100 mg/patch (10 cm × 14 cm), manufacturer: Zhejiang Saimo Pharmaceutical Co., Ltd.), in healthy participants under fasting conditions, and to estimate the corresponding pharmacokinetic parameters; and to conduct a formal human bioequivalence study using loxoprofen sodium patch (100 mg/patch (10 cm × 14 cm), licensee: LEAD CHEMICAL CO., LTD.) as the reference formulation, providing a reference for the drug's registration and clinical application.
Secondary Objective: To observe the safety, adhesion, and skin irritation of the test and reference formulations in participants under fasting conditions.